What's Happening?
Abbott has announced a partnership with Flatiron Health to integrate its Precision Oncology testing portfolio directly into Flatiron's OncoEMR, a cloud-based Electronic Medical Record (EMR) platform. This integration allows oncology providers to order
specialized cancer tests and view results within their primary clinical workflow, eliminating the need for separate portals or fragmented paperwork. The tests included in this integration are Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard. The integration aims to centralize patient data by automatically routing status updates and final test results back into the OncoEMR system. This development is particularly significant as it targets community cancer care centers, which handle the majority of cancer care in the U.S., thereby lowering the barrier to accessing advanced genomic and oncological diagnostics.
Why It's Important?
The integration of Abbott's Precision Oncology portfolio into Flatiron Health's OncoEMR is a significant advancement in streamlining cancer care. By embedding these tests directly into the daily EMR systems of community clinics, the partnership reduces administrative burdens on clinicians, allowing them to focus more on patient care. This move is expected to enhance the speed and efficiency of cancer diagnosis and treatment decisions, ultimately improving patient outcomes. The integration also represents a shift towards more connected, data-driven healthcare, which is crucial in the fight against cancer. As community clinics are the primary providers of cancer care in the U.S., this development could have a widespread impact on the accessibility and quality of cancer treatment across the country.
What's Next?
The integration is expected to facilitate faster and more efficient cancer care by reducing the time between test ordering and treatment decisions. As the system becomes more widely adopted, it may lead to further innovations in how cancer care is delivered in community settings. Stakeholders, including healthcare providers and patients, are likely to benefit from improved access to precision medicine. Additionally, this partnership may encourage other healthcare technology companies to pursue similar integrations, further advancing the field of precision oncology.
